Reinventing primaquine for endemic malaria.
After sixty years of continuous use, primaquine remains the only therapy licensed for arresting transmission and relapse of malaria. The US Army developed primaquine for soldiers in a wartime crisis setting. Dosing strategies suited to that narrow population were adopted without modification or vali...
| Main Author: | |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826266899356319744 |
|---|---|
| author | Baird, J |
| author_facet | Baird, J |
| author_sort | Baird, J |
| collection | OXFORD |
| description | After sixty years of continuous use, primaquine remains the only therapy licensed for arresting transmission and relapse of malaria. The US Army developed primaquine for soldiers in a wartime crisis setting. Dosing strategies suited to that narrow population were adopted without modification or validation for the broader population of humans exposed to risk of malaria. The poor suitability of these strategies in populations exhibiting greater vulnerability to hemolytic toxicity among glucose-6-phosphate dehydrogenase deficient patients has not been addressed. Primaquine requires chemotherapeutic reinvention delivering less threatening doses by leveraging unexplored co-drug synergies. |
| first_indexed | 2024-03-06T20:45:56Z |
| format | Journal article |
| id | oxford-uuid:35e3d1c0-af57-4e2b-af0f-afcdca060ad6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:45:56Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:35e3d1c0-af57-4e2b-af0f-afcdca060ad62022-03-26T13:34:37ZReinventing primaquine for endemic malaria.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:35e3d1c0-af57-4e2b-af0f-afcdca060ad6EnglishSymplectic Elements at Oxford2012Baird, JAfter sixty years of continuous use, primaquine remains the only therapy licensed for arresting transmission and relapse of malaria. The US Army developed primaquine for soldiers in a wartime crisis setting. Dosing strategies suited to that narrow population were adopted without modification or validation for the broader population of humans exposed to risk of malaria. The poor suitability of these strategies in populations exhibiting greater vulnerability to hemolytic toxicity among glucose-6-phosphate dehydrogenase deficient patients has not been addressed. Primaquine requires chemotherapeutic reinvention delivering less threatening doses by leveraging unexplored co-drug synergies. |
| spellingShingle | Baird, J Reinventing primaquine for endemic malaria. |
| title | Reinventing primaquine for endemic malaria. |
| title_full | Reinventing primaquine for endemic malaria. |
| title_fullStr | Reinventing primaquine for endemic malaria. |
| title_full_unstemmed | Reinventing primaquine for endemic malaria. |
| title_short | Reinventing primaquine for endemic malaria. |
| title_sort | reinventing primaquine for endemic malaria |
| work_keys_str_mv | AT bairdj reinventingprimaquineforendemicmalaria |